Treatment | n | -log EC50 (M) | Emax (%) | Hill slope | n | -log EC50 (M) a d | Emax (%) b d | Hill slope c f |
---|---|---|---|---|---|---|---|---|
 | Saline | Angiotensin II | ||||||
controls | 48 | 8.3(0.1) | 97(1) | 2.1(0.1) | 52 | 8.1(0.1) | 96(1) | 1.8(0.1) |
L-NAME | 12 | 7.8(0.2)i | 90(2)j | 1.9(0.6)j | 24 | 7.8(0.1) j | 85(2)i | 1.3(0.2) |
indomethacin | 12 | 8.4(0.1) | 96(1) | 2.1(0.5) | 17 | 7.9(0.1)h | 93(1) | 1.5(0.2) |
L-NAME + indomethacin | 10 | 8.0(0.1) | 90(2)k | 1.2(0.3) | 18 | 7.4(0.1)g i | 81(4)g i | 1.3(0.2) |
NS398 3 μM | 5 | 8.2(0.4) | 92(4) | 2.3(0.3) | 7 | 7.9(0.1) | 93(2) | 4.7(1.6)h i |
FR122047 | 12 | 8.3(0.1) | 96(1) | 2.0(0.3) | 15 | 7.8(0.1)h k | 91(2) | 1.7(0.3) |
NS398 + FR122047 | 5 | 8.0(0.2) | 92(2) | 0.9(0.1) | 8 | 8.0(0.2) | 94(2) | 2.4(0.4) |
CAY10441 | 7 | 8.3(0.2) | 96(2) | 1.8(0.3) | 7 | 8.0(0.1) | 96(1) | 2.2(0.4) |
AH6809 + L798106 + L161982 | 6 | 8.5(0.3) | 97(1) | 1.5(0.3) | 6 | 8.0(0.1) | 96(1) | 2.2(0.4) |
SQ29548 | 4 | 8.5(0.2) | 96(1) | 0.8(0.2) | 6 | 7.9(0.2) | 93(2) | 2.0(0.4) |
NS398 0.3 μM | 7 | 8.1(0.1) | 98(1) | 2.1(0.3) | 6 | 7.8(0.1) | 95(1) | 2.4(0.6) |